Factors Affecting Treatment Discontinuation and Treatment Outcome in Patients with Schizophrenia in Korea: 10-Year Follow-Up Study
0
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Objective There have been few long-term studies that have assessed factors influencing treatment discontinuation and long-term outcome of schizophrenia in Korea. The present study aimed to evaluate factors affecting treatment discontinuation and treatment outcome, after 10 years, in patients with schizophrenia. Methods Among hospitalized patients between 1997 and 1999, 191 patients were given continuous follow-up service. We examined the clinical characteristics and outcome of patients who remained in treatment. Regression analyses were used to find any clinical factors affecting treatment discontinuation. Results One hundred thirty-three patients (71.12%) discontinued the treatment. The treatment retention group contained more female patients, paranoid-type patients, patients who had shown self-harming behavior, patients receiving clozapine, and patients with good medication compliance. The recovery rate was 25%. However, 42.3% did not have gainful employment. Further, most patients couldn’t live independently. Conclusion The results show the importance of gender, patient behavior, medication, and medication compliance in predicting treatment discontinuation in patients with schizophrenia.
Abstract
Objective There have been few long-term studies that have assessed factors influencing treatment discontinuation and long-term outcome of schizophrenia in Korea. The present study aimed to evaluate factors affecting treatment discontinuation and treatment outcome, after 10 years, in patients with schizophrenia. Methods Among hospitalized patients between 1997 and 1999, 191 patients were given continuous follow-up service. We examined the clinical characteristics and outcome of patients who remained in treatment. Regression analyses were used to find any clinical factors affecting treatment discontinuation. Results One hundred thirty-three patients (71.12%) discontinued the treatment. The treatment retention group contained more female patients, paranoid-type patients, patients who had shown self-harming behavior, patients receiving clozapine, and patients with good medication compliance. The recovery rate was 25%. However, 42.3% did not have gainful employment. Further, most patients couldn’t live independently. Conclusion The results show the importance of gender, patient behavior, medication, and medication compliance in predicting treatment discontinuation in patients with schizophrenia.
참고문헌 (23)
- Hong J, "The cost of relapse in patients with schizophrenia in the European SOHO (Schizophrenia Outpatient Health Outcomes) study", Prog Neuropsychopharmacol Biol Psychiatry, 33, pp.835~841 (2009)
- Wu EQ, "The economic burden of schizophrenia in the United States in 2002", J Clin Psychiatry, 66, pp.1122~1129 (2005)
- Bromet EJ, "Long-term diagnostic stability and outcome in recent first-episode cohort studies of schizophrenia", Schizophr Bull, 31, pp.639~649 (2005)
- Manschreck TC, "The CATIE schizophrenia trial: results, impact, controversy", Harv Rev Psychiatry, 15, pp.245~258 (2007)
- Lindenmayer JP, "Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response", J Clin Psychiatry, 70, pp.990~996 (2009)
- Peuskens J, "Belgian Schizophrenia Outcome Survey-results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol", Eur Psychiatry, 24, pp.154~163 (2009)
- Perkins DO, "Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode", Schizophr Res, 83, pp.53~63 (2006)
- Robinson DG, "Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder", Schizophr Res, 57, pp.209~219 (2002)
- Perkins DO, "Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study", J Clin Psychiatry, 69, pp.106~113 (2008)
- Fenton WS, "Determinants of medication compliance in schizophrenia: empirical and clinical findings", Schizophr Bull, 23, pp.637~651 (1997)
- Dolder CR, "Antipsychotic medication adherence: is there a difference between typical and atypical agents?", Am J Psychiatry, 159, pp.103~108 (2002)
- Garcìa-Cabeza I, "Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study).", BMC Psychiatry, 1, pp.7~ (2001)
- Glick ID, "Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders", Int Clin Psychopharmacol, 17, pp.65~68 (2002)
- Limosin F, "Ten-year prospective follow-up study of the mortality by suicide in schizophrenic patients", Schizophr Res, 94, pp.23~28 (2007)
- Mullins CD, "Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia", Schizophr Res, 98, pp.8~15 (2008)
- Kamali M, "A prospective evaluation of adherence to medication in first episode schizophrenia", Eur Psychiatry, 21, pp.29~33 (2006)
- Saha S, "A systematic review of the prevalence of schizophrenia", PLoS Med, 2, pp.e141~ (2005)
- Siegel SJ, "Prognostic variables at intake and long-term level of function in schi-zophrenia", Am J Psychiatry, 163, pp.433~441 (2006)
- Bagnall AM, "A systematic review of atypical antipsychotic drugs in schizophrenia", Health Technol Assess, 7, pp.1~193 (2003)
- Davis JM, "A meta-analysis of the efficacy of second-generation antipsychotics", Arch Gen Psychiatry, 60, pp.553~564 (2003)
- Voruganti L, "Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life", Schizophr Res, 43, pp.135~145 (2000)
- Chee KY, "Outcome study of first-episode schizophrenia in a developing country: quality of life and antipsychotics", Soc Psychiatry Psychiatr Epidemiol, 44, pp.143~150 (2009)
- Jones PB, "Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)", Arch Gen Psychiatry, 63, pp.1079~1087 (2006)